{"id":"NCT00483938","sponsor":"Hoffmann-La Roche","briefTitle":"The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)","officialTitle":"The Individualized Management With Pegasys and Ribavirin Offering Viral Eradication (IMPROVE) Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-06","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2007-06-08","resultsPosted":"2017-01-23","lastUpdate":"2017-01-23"},"enrollment":236,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"Pegylated-interferon Alfa-2a","otherNames":["Pegasys"]},{"type":"DRUG","name":"Ribavirin","otherNames":["Copegus"]}],"arms":[{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group A)","type":"EXPERIMENTAL"},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group B)","type":"EXPERIMENTAL"},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group C)","type":"EXPERIMENTAL"},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group D)","type":"EXPERIMENTAL"},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group E)","type":"EXPERIMENTAL"},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group F)","type":"EXPERIMENTAL"},{"label":"Pegylated-interferon Alfa-2a + Ribavirin (Group NR)","type":"EXPERIMENTAL"}],"summary":"This study will compare the efficacy and safety of treatment with pegylated-interferon alfa-2a plus ribavirin in participants with non-genotype 2/3 CHC who, after 12 weeks of study treatment, have undetectable hepatitis C virus (HCV)-ribonucleic acid (RNA) or a greater than or equal to (\\>=) 2 log10 drop in HCV-RNA. Participants will be randomized to receive pegylated-interferon alfa-2a 180 micrograms subcutaneously weekly plus ribavirin (1000-1400 milligram \\[mg\\]) orally daily for the specified duration, followed by 24 weeks of treatment-free follow-up. Participants with detectable HCV-RNA and less than (\\<) 2 log10 drop in HCV-RNA at week 12 will discontinue therapy.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virological Response (SVR) (Groups A and B)","timeFrame":"At 24-week untreated follow-up visit (up to 72 weeks for Group A, up to 96 weeks for Group B)","effectByArm":[{"arm":"Pegylated-interferon Alfa-2a + Ribavirin (Group A)","deltaMin":48.8,"sd":null},{"arm":"Pegylated-interferon Alfa-2a + Ribavirin (Group B)","deltaMin":39.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.510"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":23,"countries":["United States","Canada"]},"refs":{"pmids":["22050141"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":41},"commonTop":["Flu-like symptoms (fever, chills, headache, aches/pains)","Skin (injection site reactions, rashes, pruritus)","Emotional/mental (depression, anxiety, irritability, forgetfulness, confusion, anger)","Fatigue","Insomnia"]}}